Silence Therapeutics PLC
SLN5.950USD
-0.220-3.57%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
843.06MCap. mercado
PérdidaP/E TTM
Más Datos de Silence Therapeutics PLC Compañía
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Información de la empresa
Símbolo de cotizaciónSLN
Nombre de la empresaSilence Therapeutics PLC
Fecha de salida a bolsaJan 05, 2010
Director ejecutivoMr. Craig A. Tooman
Número de empleados116
Tipo de seguridadDepository Receipt
Fin del año fiscalJan 05
Dirección72 Hammersmith Road
CiudadLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalW14 8TH
Teléfono442034576900
Sitio Webhttps://www.silence-therapeutics.com/
Símbolo de cotizaciónSLN
Fecha de salida a bolsaJan 05, 2010
Director ejecutivoMr. Craig A. Tooman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Accionistas
Accionistas
Proporción
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
24.38%
Investment Advisor
18.47%
Investment Advisor/Hedge Fund
10.53%
Hedge Fund
7.10%
Research Firm
5.08%
Venture Capital
3.35%
Private Equity
2.43%
Other
28.65%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
130
33.69M
71.34%
-14.09M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.93%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
iShares Biotechnology ETF
Proporción0.01%
SPDR S&P International Small Cap ETF
Proporción0.01%
ActivePassive International Equity ETF
Proporción0%
Tema Heart & Health ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
